$100 million gift given to fight cancer

Sep 22, 2006

The Starr Foundation has donated $100 million to promote cancer research at four New York institutions and one in Massachusetts.

The gift from one of the United States' biggest philanthropies, to be distributed over five years, will go to Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell College and Cold Spring Harbor Laboratory in New York and the Broad Institute, a research center created by Harvard and MIT.

The groups will meet to decide how to spend the money.

Starr gave $50 million last year for a collaborative stem cell research effort by Cornell, Rockefeller and Sloan-Kettering.

Copyright 2006 by United Press International

Explore further: The fine line between breast cancer and normal tissues

add to favorites email to friend print save as pdf

Related Stories

Treatment plant engineered for rising oceans

Jan 29, 2014

Climate change may not have been as prominent in the headlines in the 1980s as it is today, but it was certainly on the minds of engineers designing a new sewage-treatment plant for Boston.

Hepatitis C-like viruses identified in bats and rodents

Apr 22, 2013

As many as one in 50 people around the world is infected with some type of hepacivirus or pegivirus, including up to 200 million with hepatitis C virus (HCV), a leading cause of liver failure and liver cancer. There has been ...

Recommended for you

Gene linked to development of skin cancer in mice

15 minutes ago

(Medical Xpress)—New research on an enzyme linked to cancer development shows that 37 percent of mice that produce excessive quantities of the enzyme developed skin tumors within four to 12 months of birth, ...

The fine line between breast cancer and normal tissues

16 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

17 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

User comments : 0